《NCCN临床实践指南_慢性髓性白血病(2019.V1)英文版》由会员分享，可在线阅读，更多相关《NCCN临床实践指南_慢性髓性白血病(2019.V1)英文版（82页珍藏版）》请在金锄头文库上搜索。
1、Chronic Myeloid Leukemia Version 1 2019 August 1 2018 NCCN org NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines Continue Version 1 2019 08 01 18 National Comprehensive Cancer Network Inc 2018 All rights reserved The NCCN Guidelines and this illustration may not be reproduced in any form
2、 without the express written permission of NCCN NCCN Kristina Gregory RN MSN OCN Hema Sundar PhD Continue NCCN Guidelines Panel Disclosures Hematology Hematology oncology Medical oncology Internal medicine Pathology Bone marrow transplantation Jason Gotlib MD MS Stanford Cancer Institute Gabriela Ho
3、bbs MD Massachusetts General Hospital Cancer Center Madan Jagasia MD Vanderbilt Ingram Cancer Center Hagop M Kantarjian MD The University of Texas MD Anderson Cancer Center Lori Maness MD Fred and Pamela Buffett Cancer Center Leland Metheny MD Case Comprehensive Cancer Center University Hospitals Se
4、idman Cancer Center and Cleveland Clinic Taussig Cancer Institute Joseph O Moore MD Duke Cancer Institute Arnel Pallera MD St Jude Children s Research Hospital The University of Tennessee Health Science Center Philip Pancari MD Fox Chase Cancer Center Mrinal Patnaik MD Mayo Clinic Cancer Center Enkh
5、tsetseg Purev MD PhD University of Colorado Cancer Center Jerald P Radich MD Chair Fred Hutchinson Cancer Research Center Seattle Cancer Care Alliance Michael Deininger MD PhD Vice Chair Huntsman Cancer Institute at the University of Utah Camille N Abboud MD Siteman Cancer Center at Barnes Jewish Ho
6、spital and Washington University School of Medicine Jessica K Altman MD Robert H Lurie Comprehensive Cancer Center of Northwestern University Ellin Berman MD Memorial Sloan Kettering Cancer Center Ravi Bhatia MD University of Alabama at Birmingham Comprehensive Cancer Center Bhavana Bhatnagar DO The
7、 Ohio State University Comprehensive Cancer Center James Cancer Hospital and Solove Research Institute Peter Curtin MD UC San Diego Moores Cancer Center Daniel J DeAngelo MD PhD Dana Farber Brigham and Women s Cancer Center Michal G Rose MD Yale Cancer Center Smilow Cancer Hospital Neil P Shah MD Ph
8、D UCSF Helen Diller Family Comprehensive Cancer Center B Douglas Smith MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins David S Snyder MD City of Hope Comprehensive Cancer Center Kendra L Sweet MD MS Moffitt Cancer Center Moshe Talpaz MD University of Michigan Rogel Cancer Center Ja
9、mes Thompson MD Roswell Park Comprehensive Cancer Center David T Yang MD University of Wisconsin Carbone Cancer Center NCCN Guidelines Index Table of Contents Discussion Version 1 2019 08 01 18 National Comprehensive Cancer Network Inc 2018 All rights reserved The NCCN Guidelines and this illustrati
10、on may not be reproduced in any form without the express written permission of NCCN NCCN Guidelines Version 1 2019 Chronic Myeloid Leukemia Printed by Maria Chen on 8 1 2018 9 22 15 PM For personal use only Not approved for distribution Copyright 2018 National Comprehensive Cancer Network Inc All Ri
11、ghts Reserved NCCN Chronic Myeloid Leukemia Panel Members Summary of Guidelines Updates Workup CML 1 Chronic Phase CML Primary Treatment CML 2 Early Treatment Response Milestones Clinical Considerations and Second line Treatment CML 3 Advanced Phase CML Primary Treatment CML 4 Treatment Options Base
12、d on BCR ABL1 Mutation Profile CML 5 Allogeneic Hematopoietic Cell Transplantation CML 6 Risk Calculation Table CML A Definitions of Accelerated Phase and Blast Phase CML B Monitoring Response to TKI Therapy and Mutational Analysis CML C Criteria for Hematologic Cytogenetic and Molecular Response an
13、d Relapse CML D Criteria for Discontinuation of TKI Therapy CML E Management of Toxicities CML F Management of Bosutinib Toxicity CML F 1 of 6 Management of Dasatinib Toxicity CML F 2 of 6 Management of Imatinib Toxicity CML F 3 of 6 Management of Nilotinib Toxicity CML F 4 of 6 Management of Omacet
14、axine Toxicity CML F 5 of 6 Management of Ponatinib Toxicity CML F 6 of 6 The NCCN Guidelines are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment Any clinician seeking to apply or consult the NCCN Guidelines is expected to use
15、independent medical judgment in the context of individual clinical circumstances to determine any patient s care or treatment The National Comprehensive Cancer Network NCCN makes no representations or warranties of any kind regarding their content use or application and disclaims any responsibility
16、for their application or use in any way The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network All rights reserved The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN 2018 Clinical Trials NCCN believes that the best management for any patient with cancer is in a clinical trial Participation in clinical trials is especially encouraged To find clinical trials online at NCCN Member Institutions click
